Bioton and GSK in talks about new collaboration agreements

Bioton announced that it has signed a letter of intent with GlaxoSmithKline (GSK) to negotiate collaboration agreements for the commercialisation by GSK of the Polish firm’s insulin products in a number of foreign markets, mainly developing and emerging ones.

The document grants GSK exclusivity until 28 February to negotiate with Bioton the terms of supply, licensing and other agreements involving the Polish firm’s insulin products, including insulin analogs and insulin pens, on the following markets: the Commonwealth of Independent States (CIS) countries, Asia and the Pacific (excluding Japan and China), the Middle East, Latin America and Africa.

The news comes less than a month after Bioton signed an agreement with GSK giving the global pharma firm exclusive rights to the marketing, distribution and sale of Gensulin, its flagship human insulin product, and Gensupen, its insulin pen, on the Russian market, for a period of 15 years.

Bioton is also in talks about similar agreements with Actavis.